NICE provided a positive recommendation for Welireg access via the Cancer Drugs Fund (CDF) for treating tumours associated with von Hippel-Lindau (vHL) disease. Welireg is therefore now available in England and Wales via the NHS (in addition to Scotland which was previously granted reimbursement by the SMC in October 2023). MSD is therefore sending an additional DHPC mailing to HCPs in England and Wales to advise them that patients must be provided with a patient alert card.

DHPC: Minor Editorial updates : The letter dated ‘October 2024’ should replace the letter dated ‘December 2023’. Correction of the spelling for ‘Executive’ in the signatory field. Addition of ‘GB-BEL-00063 / Date of Preparation: October 2024’ in the footer